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Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder that causes
selective death of motor neurons followed by paralysis and death. A subset of ALS cases is
caused by mutations in the gene for Cu, Zn superoxide dismutase (SOD1), which impart a
toxic gain of function to this antioxidant enzyme. This neurotoxic property is widely
believed to stem from an increased propensity to misfold and aggregate caused by decreased
stability of the native homodimer or a tendency to lose stabilizing posttranslational
modifications. Study of the molecular mechanisms of SOD1-related ALS has revealed a
complex array of interconnected pathological processes, including glutamate excitotoxicity,
dysregulation of neurotrophic factors and axon guidance proteins, axonal transport defects,
mitochondrial dysfunction, deficient protein quality control, and aberrant RNA processing.
Many of these pathologies are directly exacerbated by misfolded and aggregated SOD1 and/
or cytosolic calcium overload, suggesting the primacy of these events in disease etiology
and their potential as targets for therapeutic intervention.
I. ALS Is a Deadly Neurodegenerative Disorder
Amyotrophic lateral sclerosis (ALS) was first described by the noted French neurologist
Jean-Martin Charcot in 1869, who connected the progressive paralytic syndrome with
lesions in both white and gray matter of the central nervous system (CNS).1 Over 140 years
later, ALS is the most common adult-onset motor neuron disorder, affecting approximately
1–2 per 100,000 people worldwide. Considering the short course of disease progression
(death/tracheotomy typically within 2–5 years of diagnosis), 1 in every 800 individuals is
expected to face ALS in his/her lifetime.2–4
As described by Charcot, ALS involves degeneration of the upper motor neurons (UMN) of
the motor cortex and of the lower motor neurons (LMN), which extend through the
brainstem and spinal cord to innervate skeletal muscle. Though the upper and lower motor
systems are known to be interconnected, controlling voluntary muscle movement in concert,
the primary site of dysfunction in ALS has long been a source of debate.5–7 Questions of
UMN/LMN primacy aside, ALS is clearly specific for motor neurons and largely spares
cognitive ability, sensation, and autonomic nervous functions. Muscles controlling eye
movement and the pelvic floor are the only skeletal musculature left unaffected. However, in
a minority of cases (5–10%), patients also develop frontotemporal lobar dementia (FTLD).
It has been suggested that a greater percentage of patients experience some cognitive change
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Clinical presentation varies but most commonly consists of weakness, fasciculations
(twitching muscles), and/or hyperreflexivity of facial muscles (bulbar onset) or limbs (spinal
onset). Interestingly, initial symptoms usually appear at a focal site and later spread along
contiguous anatomic paths.9 Diagnosis is achieved by a combination of clinical examination
and electromyography (EMG), in which positive, sharp waves and fibrillation potentials
provide evidence for active denervation. The El Escorial criteria were developed in 1990
and are still utilized to diagnose and classify ALS cases as “possible,” “probable,” or
“definite”10 (Fig. 1). Guidelines on implementation of the El Escorial criteria have been
revised to place greater emphasis on electrophysiological abnormalities, which can be
detected earlier and thus facilitate timely diagnosis.11
II. Etiology of ALS
The majority of ALS cases (≈82%) are sporadic (SALS), having no apparent heritability.9
Up to 5% of SALS cases are caused by mutations in the 43-kDa trans-activating response
region DNA-binding protein (TDP-43). TDP-43 mutations have also been linked to ≈3% of
inherited, or “familial” ALS (FALS).12 The most commonly occurring mutations in patients
with FALS are found in the gene for Cu, Zn superoxide dismutase (SOD1) and account for
approximately 20% of all FALS.13,14 Most of these mutations are missense mutations that
cause autosomal dominant ALS, except the D90A polymorphism, which can also behave as
a recessive mutation.15 FALS-causative mutations have also been found in genetic loci
corresponding to alsin, a guanine exchange factor for Rac1 that plays a role in cytoskeletal
dynamics16,17; senataxin, a DNA/RNA helicase that may be involved in RNA
processing18,19; vesicle-associated membrane protein-associated protein B (VAPB), which
facilitates intracellular vesicular trafficking20; and angiogenin (ANG)21–23 (Table I). Some
polymorphisms found in patients with ALS do not segregate completely with disease and
may represent genetic risk factors rather than causative mutations. Mutations in the
neurofilament-heavy subunit,24,25 vascular endothelial growth factor (VEGF),26 and ciliary
neurotrophic factor (CNTF)27,28 fall under this category. All genetic loci that have been
reported as putative modifiers of ALS susceptibility are listed in the ALS Online Genetics
Database (http://alsod.iop.kcl.ac.uk).
There is evidence to suggest that specific environmental factors play a prominent role in the
etiology of some ALS cases. Geographically limited populations with dramatically increased
ALS incidence, such as inhabitants of the Kii peninsula in Japan,29 the Chamorro people of
Guam, Gulf War veterans,30,31 and Italian soccer players,32 certainly lead one to suspect the
environment as a potential modifier of disease susceptibility. There also have been reports of
ALS in individuals with intense exposure to particular stressors, such as harsh chemicals and
heavy metals,33,34 viral infection,35 electrical shock,36 and traumatic nerve injury.37 Most of
these reports, however, involve a very small number of cases and do not permit rigorous
evaluation of these stressors as potential risk factors for ALS.
The most convincing instance of a causal link between ALS and toxin exposure is the case
of the Chamorro population. A cycad indigenous to Guam produces the neurotoxin β-
methylamino-L-alanine (BMAA) in its seeds, which are eaten by flying foxes as well as
ground into flour by the Chamorro. While the dosage of BMAA resulting from a reasonable
human consumption of cycad flour is far below the threshold necessary to provoke
neurodegeneration in primates,38 this potent neurotoxin is enriched 100-fold in the tissues of
the flying fox, a delicacy to the Chamorro.39,40 Furthermore, BMAA is found in the brain
tissue from Chamorros who succumb to ALS, but not those who die of other causes, and the
prevalence of ALS among this population dropped after overhunting thinned the flying fox
population.39 While providing a convincing causal link between BMAA exposure and ALS,
it is tempting to dismiss the case of the Chamorro as inapplicable to disease risk in the
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general population. However, BMAA-producing cyanobacteria are present in many
ecosystems, and a recent study of Baltic Sea marine life revealed that BMAA is
concentrated in the tissues of organisms at higher trophic levels, such as fish and mollusks,
that are consumed by humans.41 BMAA also was found in cyanobacteria-containing sand
from Qatar,42 raising the possibility that Gulf veterans may have been exposed to this toxin
through inhalation. Furthermore, the incidence of ALS diagnosis is elevated 10–25–fold
among residents of Enfield, New Hampshire, a town bordering Lake Mascoma, which is
subject to frequent “blooms” of cyanobacteria.43 While no conclusive statements can be
made from these few examples, the worldwide prevalence of cyanobacteria seems a
compelling reason to investigate ALS risk associated with BMAA exposure.
III. SOD1-Related Pathology as a General Model for ALS
The discovery of SOD1's role in FALS14 offered the first insight into the molecular
mechanisms of ALS, and the study of SOD1-mediated pathology has contributed much to
our current understanding of the disease. The majority of in vivo work has utilized
transgenic mice expressing FALS mutants of human SOD1, which develop a progressive
motor neuron syndrome reminiscent of the human ALS phenotype (reviewed in Ref. 44).
The sporadic disease differs little clinically from SOD1-related FALS, leading to the
widespread supposition that all cases of ALS share some common mechanism(s) of
pathology.2,45,46 In reviewing the proposed molecular bases of ALS, we focus on the
contribution of SOD1, a well-studied cause of ALS that may exhibit pathogenic mechanisms
common to other forms of the disease.
IV. Misfolding and Aggregation Is the Most Likely Source of SOD1 Toxicity
SOD1 is a ubiquitous cytosolic enzyme whose primary function is the dismutation of the
superoxide radical  to a less oxidizing species (H2O2) via a bound Cu2+ ion. Although
this enzyme plays an important role as a cellular antioxidant, the ability of SOD1 mutants to
selectively kill motor neurons is not linked to a loss of dismutase function. Not only do
many FALS mutants retain enzymatic activity at or near wild-type levels,47–49 but SOD1
null mice do not exhibit neurodegeneration.50 Furthermore, the toxicity of SOD1 mutants
cannot be reversed by coexpression of wild-type SOD1.51 This evidence has led to
widespread acceptance of the hypothesis that SOD1 mutants acquire a novel toxic property
independent of their enzymatic function.
Despite over 15 years of research, the mode(s) by which SOD1 mutants selectively kill
motor neurons have not been clearly delineated. However, a large body of evidence
implicates a common propensity to misfold and aggregate as the primary toxic gain of
function. Destabilization of the native fold is an attractive hypothesis for SOD1 mutant
pathogenicity, offering a plausible explanation for the common disease outcome of over 140
mutants spanning the sequence and structure. Early in silico studies by our laboratory
predicted that a majority of SOD1 mutations would destabilize the native fold or quaternary
structure,52 a trend that since has been verified experimentally.53–56 Especially severe
destabilization caused by certain mutations could account for their inherently higher
aggressiveness (short disease duration).57,58 Indeed, several recent analyses of in vitro
SOD1 mutant behavior and FALS patient survival showed that protein instability and
increased aggregation rate correlated with decreased survival time59,60 (Fig. 2).
Furthermore, the presence of SOD1-immunoreactive proteinaceous aggregates in SALS
patient motor neurons62–65 suggests that aberrant oligomerization of SOD1 could be a
common feature of ALS, regardless of genotype. It thus appears that ALS is a protein
conformational disorder, akin to other neurodegenerative diseases such as Alzheimer's,
Parkinson's, and Huntington's.2
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Though a primary role for SOD1 aggregation in FALS seems likely, deconstruction of the
molecular determinants and mechanisms of this process is incomplete. SOD1 is an
extremely stable enzyme in its fully mature, homodimeric form, remaining active in the
presence of 6M guanidinium chloride or 8M urea.66,67 SOD1 owes its extraordinary stability
largely to the coordination of Zn2þ, which constrains the relatively unstructured electrostatic
and zinc-binding loops, “tethering” them together and protecting the protein core, an eight-
stranded Greek key β-barrel53,68,69 (Fig. 3). The catalytic copper ion and an intrasubunit
disulfide bridge between Cys-57 and Cys-146 appear to contribute relatively little to
monomer thermodynamic stability, but the latter modification constrains loop mobility and
facilitates dimer formation.66,68,74 Metal-bound, disulfide-oxidized SOD1 forms an
exceptionally stable homodimer, with low nanomolar binding affinity.75,76 These maturation
events are mutually interdependent—metal binding promotes disulfide bond formation,
disulfide bond formation and metal binding promote dimerization, and dimeric SOD1 is
more resistant to disulfide reduction/metal loss.68,75,77
In vitro studies show that dimer dissociation is a necessary initiating step in SOD1
aggregation.76,78 The resultant monomeric SOD1 is more susceptible to the loss of the
stabilizing zinc ion and disulfide bridge,79,80 leading to freer loop movement81 and exposure
of β-barrel edge strands.68,82 Dynamical studies of wild-type and FALS mutant SOD1
revealed a transient “excited state” whose population is enhanced by mutations and zinc
loss, but unaffected by disulfide status.83 Increased surface hydrophobicity of metal-free,
disulfide-reduced mutant SOD1 was shown directly by Tiwari et al. using 1-
anilinonaphthalene-8-sulfonic acid (ANS), a fluorescent dye that binds to hydrophobic
surfaces.84 Munch et al. obtained similar results using a different hydrophobic dye, Sypro
Orange, and found that increased exposure of hydrophobic regions precedes aggregation.85
A general model of SOD1 aggregation in ALS has emerged in which dimer dissociation and
subsequent metal loss (and/or disulfide reduction) induce structural distortions that favor
assembly into non-native oligomers (oligomers other than the native homodimer) (Fig. 4).
FALS mutations promote aggregation by increasing the tendency of SOD1 to lose its
stabilizing posttranslational modifications and/or by decreasing the intrinsic stability of the
apo-monomer.52,54–56,68,86–88 Substantial gaps remain in our understanding of the
relationship between SOD1 aggregation and ALS pathology. These pertain to aggregate
structure, mechanism of formation, and toxicity.
A. SOD1 Aggregate Structure
No high-resolution structural information is available for misfolded monomeric SOD1 or
nonnative oligomers. The transient nature of many structurally-perturbed SOD1 species
makes their isolation for study impractical. However, misfolded dimeric or monomeric
SOD1 can be detected using an antibody specific for residues 145–151, which are normally
buried within the native dimer interface.89 SOD1 monomers with a more substantially
disrupted fold can be tracked using an antibody recognizing the natively buried residues of β
strand 4 (residues 42–48).90 Chromatographic methods have also been utilized to isolate
misfolded SOD1 using their affinity to hydrophobic resins.91 Continued study using these
and similar methods will be useful in tracking the spatial and temporal distribution of
misfolded SOD1 in cell culture, transgenic mouse models, and patients with ALS, providing
insight into the molecular determinants and cellular consequences of SOD1 destabilization.
Electron microscopic, immunohistological, and biochemical studies have shed some light on
the structural properties of SOD1 aggregates. Both insoluble, detergent-resistant aggregates
and soluble oligomers have been noted in cell culture, transgenic mice, and in
vitro.63,64,92–94 These species contain metal-free SOD1 that is full length and usually lacks
the native disulfide bridge.95 Aggregates formed in vitro under near-physiological
conditions are often fibrillar and bind thioflavin T (ThT+, suggestive of amyloid
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character),86,96–98 while in vivo aggregates sometime appear amorphous or pore-shaped and
do not always bind amyloid-sensitive dyes.90,93,99–101 Soluble misfolded SOD1 populates a
wide range of oligomeric states and also accumulates as non-native monomers, dimers, or
trimers.62,91,96 The instability of some soluble oligomers may preclude the use of static
structural techniques, such as X-ray crystallography, to determine structural details, but
solution-state methods such as nuclear magnetic resonance (NMR) or limited proteolysis,
especially coupled with computational structural modeling, may yield insights into their
conformations.
B. Mechanism of SOD1 Aggregation
The likelihood that misfolded SOD1 samples a multitude of conformational states also
complicates detailed mechanistic study of oligomer formation. However, it is clear that
posttranslational modifications of the SOD1 polypeptide modulate oligomer formation to
some extent. As discussed above, the native intramolecular disulfide bridge and metal
binding both impart exceptional stability to SOD1 and, unsurprisingly, loss of these factors
drives misfolding and aggregation. However, reduction of the native Cys-57–Cys-146
disulfide has been putatively linked to the initiation, but not elongation, of amyloid-like
fibril formation in vitro.86,97 Disulfide-intact, but metal-free, SOD1 incubated at
physiological pH and temperature can be induced to aggregate by disrupting noncovalent
interactions with a chaotrope, but treatment with a reducing agent instead results in a 20-fold
shorter lag period.97 Disulfide bond reduction, while apparently dispensable for fibril
formation in vitro, may specifically accelerate nucleation. Indeed, the presence of a small
amount of disulfide-reduced wild-type or mutant SOD1 appeared to “recruit” disulfide-
intact wild-type SOD1 into fibrils without the need for additional reducing agent.97 The
mechanism by which disulfide-reduced SOD1 facilitates fibril nucleation has not yet been
demonstrated, although the requirement of Cys-57 and Cys-146 suggests that intermolecular
cross-linking between these two residues may play a role.97 It is also unclear whether in
vivo SOD1 aggregation, which is not always amyloid-like, proceeds by elongation of nuclei.
The two free cysteines in SOD1, at positions 6 and 111, also appear to be involved in SOD1
oligomer assembly. In vitro aggregation of metal-free wild-type SOD1 coincides with a loss
of free cysteines and oligomer formation is attenuated by mutations at either or both
sites,96,102 leading to the hypothesis that intermolecular disulfide cross-linking mediates
oligomerization. However, more recent studies in mutant SOD1 transgenic mice show that
aberrant disulfide linkages are present only in large-scale aggregates appearing late in the
disease.103,104 A secondary role for intermolecular disulfide cross-linking in aggregation is
unsurprising given the reducing environment of the cytosol and may be due to “trapping” of
SOD1 in a misfolded state after an initial destabilizing trigger, such as Zn2+ loss or altered
conformational dynamics resulting from mutation.87,88 Cell culture experiments reveal a key
role for Cys-111 in the promotion of SOD1 oligomerization, as mutation of this residue, but
not Cys-6, attenuated oligomer formation and protected cells from mutant SOD1-mediated
toxicity.105 It could be that the higher solvent accessibility of Cys-111 (and thus, increased
susceptibility to aberrant intermolecular disulfide cross-linking) accounts for its particular
importance in SOD1 oligomerization. However, recent investigations by our laboratory offer
an alternate interpretation of this phenomenon. We recently confirmed earlier reports that
Cys-111 forms a mixed disulfide with glutathione and showed that this modification is
abundant in human tissue. Interestingly, Cys-111 glutathionylation triggers dissociation of
both wild-type and FALS mutant dimers in vitro, thus promoting the first step in SOD1
aggregation.105a The characterization of intermolecular disulfide formation as a nonessential
late event in oligomerization suggests that Cys-111 may primarily promote aggregation by
its ability to be glutathionylated, a modification that destabilizes the native homodimer.
Treatments used to prevent Cys-111-mediated SOD1 aggregation in previous cell culture
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experiments,105 such as addition of a reducing agent and overexpression of glutaredoxin,
would remove the glutathione moiety in addition to reducing intermolecular disulfides.
Therefore, further study would be useful to resolve the contributions of Cys-111
glutathionylation and intermolecular disulfide bond formation in oligomer formation.
An emerging question in the study of mutant-mediated SOD1 aggregation is the extent of
involvement of the wild-type protein. Since most FALS patients with SOD1 mutations are
heterozygous, recent studies have utilized transgenic mice expressing both human wild-type
and FALS mutant SOD1 to more accurately recapitulate SOD1 behavior in vivo.
Coexpression of SOD1WT exacerbates the disease phenotypes of SOD1G93A106,107
SOD1G85R108 SOD1L126Z, and SOD1A4V mice,92 hastening the appearance of cellular
pathologies and shortening survival times (Fig. 5). The effect of the wild-type protein on
SOD1A4V mice is particularly dramatic; even though FALS patients with this mutation
exhibit particularly rapid disease progression, mice expressing only SOD1A4V do not
develop motor neuron disease within their lifetimes.48 The toxic effect of coexpressing wild-
type protein may be a simple issue of protein copy number. An earlier study of G85R mice51
did not find any effect of human wild-type coexpression on survival, but both SOD1G85R
and SOD1WT were expressed at lower levels than in the more recent model.108 The
observation that mutant SOD1 toxicity depends heavily on protein abundance, while not
surprising, is troubling since nearly all mutant SOD1 transgenic mice substantially
overexpress the protein.44 However, mice overexpressing SOD1WT alone, while exhibiting
minor deficits in motor function, do not experience paralysis or die prematurely.107 Thus,
FALS mutants clearly possess intrinsic pathogenicity independent of gene dosage. Mutant-
wild-type heterodimers and disulfide-linked aggregates containing both wild-type and
mutant SOD1 have been observed,92,108 suggesting that wild-type SOD1 is “recruited” into
non-native oligomers by pathogenic mutants, possibly under conditions of oxidative stress.
These studies present an incomplete picture of the role of SOD1WT in aggregation but
highlight the need for further scrutiny of the physiological relevance of commonly used
transgenic mouse models.
C. Toxicity of SOD1 Aggregates
While misfolding and aggregation has been convincingly linked to ALS pathogenesis, the
species responsible for motor neuron death has not been identified. Insoluble inclusion
bodies appear in brain stem and spinal cord coincident with symptom onset and accumulate
progressively in the terminal stages,109–113 leading to an initial belief that large-scale
aggregates are themselves toxic. However, the ability to detect soluble misfolded SOD1 led
to the discovery that these non-native forms are present from birth91,114 and selectively
enriched in motor neurons89,91 of FALS transgenic mice. It thus appears that small
misfolded SOD1 may be the actual toxic culprit(s), present throughout life but causing
symptoms only when cells can no longer keep their deleterious effects in check. In such a
scenario, assembly of soluble misfolded SOD1 into relatively inert inclusions is expected to
be neuroprotective, a phenomenon that has been demonstrated for aggregation of Ab and
huntingtin in Alzheimer's and Huntington's diseases, respectively.115–117 However, the
relative toxicities of small soluble oligomers and large-scale aggregates of SOD1 remain to
be directly proven. Similarly, no consensus has yet been reached on the mode(s) by which
non-native SOD1 kills cells. The evidence at present, though sometimes contradictory,
identifies a diverse set of targeted organelles, signaling pathways, and other cellular
processes. In the remainder of this chapter, we will discuss the various pathological
processes occurring in ALS, with special attention to a potential causal role for misfolded
and/or aggregated SOD1.
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V. Motor Neuron Death in ALS: Apoptotic Versus Necrotic, Cell-
Autonomous Versus Non-Cell-Autonomous
Classification of motor neuron death in ALS remains controversial. Spinal cord motor
neurons of ALS patients and transgenic mice overexpress the pro-apoptotic BH3-only
protein Bax,118 and knocking out this protein in SOD1G93A mice results in delayed disease
onset.119 However, activation of “executioner” caspases (caspase-3, caspase-6, and
caspase-7) is not always seen120–122 and the morphology of dying motor neurons is often
uncharacteristic of apoptotic bodies.123,124 The current model for neuronal death in ALS is
the one that has characteristics of both apoptosis and necrosis, with “necrotic-like” and
“apoptotic-like” processes dominating in different cell types and/or disease stages that have
yet to be delineated.121,125
Another question pertaining to classification of cell death in ALS is the autonomy of this
process in motor neurons. A cell-autonomous “dying forward” process was long assumed, in
which dysfunction within motor neurons, independent of input from surrounding cells, leads
to their death and a subsequent denervation of motor endplates. However, several studies
using cell-specific expression of mutant SOD1 support a prominent role of non-neuronal
cells in promoting cell death. The most striking evidence against cell-autonomous motor
neuron death is the reported lack of ALS phenotype of transgenic mice expressing mutant
SOD1 under a neuron-specific promoter.126,127 Mice with supraendogenous neuron-specific
expression do experience neurodegeneration but show different pathological changes
compared to transgenics ubiquitously expressing FALS mutant SOD1. Symptom onset
occurs later, is diffuse rather than focal, and lacks certain morphological hallmarks such as
mitochondrial vacuolization.128 Astrocytes, supporting cells that neighbor motor neurons,
have also been proposed to turn deadly in ALS through defects in glutamate processing and
other mechanisms (see below). While mutant SOD1-expressing astrocytes exert toxicity on
motor neurons in coculture,129 astrocyte-specific expression failed to cause motor neuron
disease in mice.130 Mutant SOD1 expression limited to microglia (phagocytic cells in the
CNS) or Schwann cells, which myelinate motor axons, likewise produced no ALS
phenotype.44,131,132 Although mutant SOD1 in neurons, astrocytes, and microglia appears
insufficient to provoke ALS symptoms in isolation, knockdown in these cell types using
Cre–Lox systems or siRNA delays disease onset and/or progression in transgenic mice with
ubiquitous expression.133–135 Surprisingly, Schwann cell-specific knockout of mutant SOD1
was reported to accelerate disease progression.136 Taken together, these studies highlight the
importance of non-neuronal cells in ALS pathogenesis and progression and suggest that the
primary site of dysfunction may not be the motor neuron itself (Fig. 6).
Interestingly, skeletal muscle-specific expression of mutant, and to a lesser extent, wild-
type, SOD1 in mice was recently shown to cause early motor deficits, followed by
neuromuscular junction (NMJ) dismantlement and late-onset motor neuron loss.137 This
result is surprising in light of previous studies showing no effect of mutant SOD1
knockdown in muscle138,139 but is consistent with reports of muscular defects as the primary
pathogenic events in ALS.140,141 The ability of muscle-restricted expression of mutant
SOD1 to provoke motor neuron degeneration, as well as the precedence of neuromuscular
denervation in the disease course (Fig. 7), suggests a “dying back” model of ALS where loss
of the neuronal cell body is not the initiating event. The primacy of the NMJ in ALS
pathogenesis is further supported by studies showing that inhibition of pro-apoptotic
machinery, while completely preventing motor neuron loss in mice, did not prevent
denervation and offered little functional improvement or lifespan extension.119,142,143 The
mechanisms by which toxic signals are transmitted from muscle to NMJ to motor axons are
unknown, but a recent study of SOD1G93A mice noted increased retrograde axonal transport
of proteins related to cellular stress and death.144 Muscular overexpression of a
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mitochondrial uncoupling protein, which disrupts ATP synthesis, was also sufficient to
induce progressive NMJ dismantlement and motor neuron loss in mice.145 Loss of
compensatory reinnervation may also be involved in NMJ pathology. A skeletal muscle-
specific microRNA was recently identified that slows disease progression in SOD1G93A
mice by stimulating reformation of neuromuscular synapses with denervated muscles.146
Growing support for a “dying back” hypothesis of ALS highlights the need for additional
investigation of skeletal muscle as a primary site of pathology.
VI. ALS Comprises a Spectrum of Pathologies
On a subcellular level, ALS pathology is staggeringly complex and includes abnormalities in
nearly all cellular compartments. Many of these are undoubtedly secondary effects or
compensatory mechanisms for an initial dysfunctional “trigger,” the identification of which
has remained elusive despite nearly 20 years of research on the molecular bases of ALS. We
will review some of the more notable and well-studied pathological processes and discuss
their relevance to the initial stages of disease, when therapeutic intervention may still be
possible.
A. Excitotoxic, Inflammatory, and Oxidative Insults
In 1992, Rothstein et al. found defects in glutamate signaling in neuronal tissue from
patients who died of ALS but not Alzheimer's and Huntington's diseases,147 revealing a
unique molecular basis for ALS. This phenomenon was later attributed to the selective loss
of the astrocytic glutamate transporter EAAT2, which is crucial for prompt clearance of
glutamate from the synaptic cleft after firing.148 Both FALS and SALS patients, and mutant
SOD1 mice, have decreased levels of functional EAAT2 protein (also known as GLT1) and
increased circulating glutamate in the cerebrospinal fluid (CSF).149–152 Work in transgenic
mice confirms the importance of EAAT2/GLT1-mediated glutamate clearance to motor
neuron health. Deletion of this gene is sufficient to induce progressive
neurodegeneration,153 and genetically encoded154 or exogenously stimulated EAAT2/GLT1
overexpression155 delays symptom onset in ALS mouse models. The mechanism(s) by
which EAAT2/GLT1 is downregulated in ALS are not yet understood, and it is not clear
whether decreased mRNA synthesis/stability is a factor. Postmortem spinal cord from ALS
patients had normal EAAT2/GLT1 mRNA levels.156 However, a later analysis of
SOD1G93A mice using in situ hybridization and qRT-PCR revealed a substantial decrease in
EAAT2/GLT1 promoter activity and transcript quantity concomitant with disease onset.157
EAAT2/GLT1 is directly affected by several deleterious processes that occur in the ALS-
affected CNS, suggesting that deficiency of its transport function and subsequent glutamate
overload may be a secondary event in ALS pathogenesis. Caspase-3 activation (which is
itself a relatively late-occurring phenomenon158) results in a truncated, inactive version of
EAAT2/GLT1,159 and oxidative damage to the C-terminus of EAAT2/GLT1 diminishes its
ability to transport glutamate.160–162 EAAT2/GLT1 expression in astrocytes is also subject
to modulation by neuronal signaling, via activation of the transcription factors κB motif
binding phosphoprotein (KBBP) by presynaptic axons.157 Synapse loss and denervation in
SOD1G93A mice results in decreased astrocytic KBBP and diminished expression of
EAAT2/GLT1, revealing that the astrocytic glutamate transporter is downregulated in
response to synaptic dysfunction.157 Taken together, these lines of evidence show that
deficient glutamate reuptake by astrocytes is induced by preexisting neuronal stress, which
is further exacerbated by the resultant excitotoxicity (Fig. 8).
Prolonged hyperstimulation by glutamate induces death primarily by allowing persistent
calcium influx through the Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptors, which are specifically enriched in motor neurons.163–166
Excess Ca2+ floods into the mitochondria and overwhelms its natural buffering capacity,
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triggering reactive oxygen species (ROS) production, disrupting protein homeostasis, and
eventually activating the apoptotic machinery.167,168 Cytosolic calcium overload further
perpetuates itself by stimulating the opening of ryanodine receptors (RyR) on the
endoplasmic reticulum (ER) membrane, allowing Ca2+ release from the luminal space into
the cytosol.169 AMPA receptor-mediated calcium influx also increases mutant SOD1
aggregation in cultured motor neurons170 and mouse models of ALS,171 which produces
additional ER and mitochondrial dysfunction (see below). Glutamate excitotoxicity thus acts
synergistically with protein aggregation and mitochondrial/ER dysfunction to stress motor
neurons and activate apoptosis in SOD1-related FALS (Fig. 10). Motor neurons are
selectively vulnerable to excitotoxic stress due to their abundance of AMPA receptors and
low calcium-buffering ability.172,173 Riluzole, the as-yet sole drug approved for the
treatment of ALS, inhibits excitotoxic stress in neurons by slowing glutamate release and
blocking AMPA receptors,174–177 but confers a survival benefit of only few months.178
In addition to excessive glutamate, secreted oxidative, nitrative, and inflammatory factors
also contribute to motor neuron stress and death in ALS, as illustrated by the cytotoxic effect
of ALS patient CSF on healthy rat spinal cord cultures.179 While it has become clear that
neurons, astrocytes, and microglia are all capable of secreting pro-inflammatory cytokines
and other inducers of cellular stress and death, the relative contribution of each cell type to
the transmittance of stress signals in ALS is unresolved. Astrocytes expressing mutant
SOD1 kill wild-type motor neurons in co-culture by secreting an unidentified soluble factor
that activates the pro-apoptotic Bax protein.129 Activated microglia, which are pathologic
hallmarks in the CNS of ALS patients and mouse models,180–184 release a host of
inflammatory and proapoptotic factors. For example, cyclooxygenase-2 (COX-2) and
inducible nitric oxide synthase (iNOS) are activated, resulting in enhanced production of
prostaglandins and nitric oxide (NO), respectively,185 and programmed death signals such as
the Fas ligand (FasL) and tumor necrosis factor-alpha (TNF-α) are released.185,186 A great
deal of crosstalk exists between the cellular responses to each individual cytokine. For
example, COX-2 and iNOS are activated by TNF-α stimulation of astrocytes,187 and the
transcription of FasL in motor neurons is activated by NO.186
In cases of SOD1-related FALS, the mutant protein directly contributes to production of
extracellular stressors. First, mutant SOD1 disrupts redox regulation of NADPH oxidase
(Nox), a membrane-bound producer of extracellular superoxide, through a direct interaction
with Rac1. Oxidizing conditions normally promote the dissociation of the SOD1–Rac1
complex and cessation of Nox activation, but mutant SOD1 remains bound to Rac1 and
allows persistent superoxide production under these conditions.188 Extracellular superoxide
may then enhance neuroinflammation by stimulating microglia which are activated by
ROS189 (Fig. 10). Furthermore, mutant SOD1 may itself be a secreted factor that contributes
to neurotoxicity. Mutations in SOD1 confer an affinity for the secretory vesicle proteins
chromogranins A and B.190 Localization of the mutant protein to secretory vesicles allows
its transport from neurons and astrocytes to the extracellular space, resulting in activation of
microglia and motor neuron death.190 Neuroinflammatory and excitotoxic insults from
microglia and astrocytes are thought to primarily affect disease progression rather than
representing a primary trigger of disease.191 However, some biochemical indicators of
microglial activation, such their accumulation in the CNS and increased TNF-α production,
are present prior to symptom onset in ALS mice.186,192 Although relief of excitotoxic stress
with Riluzole offers limited survival benefit, the combination of this or similar drugs with
anti-neuroinflammatory agents may result in more satisfactory functional outcomes.
B. Dysregulation of Neurotrophic Factors and Axon Guidance Proteins
Neural networks are not static entities that remain stable indefinitely after development;
rather, they require the continuous input of neurotrophic factors and axon guidance cues
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secreted by glia and innervated muscle. Loss of survival-promoting neurotrophic signaling
has therefore been proposed as a contributing factor to motor neuron demise in ALS. In
support of this view, CNTF knockout produces progressive motor neuron death in mice193
and exacerbates neurodegeneration in the SOD1G93A model.194 Muscle-specific
overexpression of glial cell-derived neurotrophic factor (GDNF) in the G93A mouse
preserves NMJs and improves motor neuron survival,195 suggesting therapeutic potential of
neurotrophic factor supplementation. However, deficits in neurotrophic factors are not seen
in ALS patients; to the contrary, GDNF and CNTF are upregulated in muscle, CSF, and
postmortem spinal cord from ALS patients.196–199 The over-abundance of these factors in
symptomatic individuals suggests that their upregulation is part of a defensive response to
existing pathology and is ultimately insufficient to halt disease progression. In line with this
view, administration of CNTF200 or brain-derived neurotrophic factor (BDNF)201 showed
no measurable benefit to ALS patients. It is possible that neurotrophic factors hold
therapeutic potential if administered early and/or at intact NMJs (recapitulating the
beneficial muscle-specific overexpression of GDNF reported by Li et al.195), but such a
requirement likely precludes their usefulness to ALS patients.
VEGF and ANG, which are involved in maintenance of both neural networks and
vasculature, have also been implicated in ALS.202,203 VEGF, in particular, has received
significant attention as a disease-modifying factor since the discovery that diminished VEGF
expression in transgenic mice is sufficient to cause late-onset neurodegeneration.204
Furthermore, ALS patients have decreased circulating levels of VEGF in CSF compared to
healthy controls.205 Mutant SOD1 directly contributes to VEGF deficiency through binding
of the 3’-untranslated region (UTR) of VEGF mRNA, destabilizing transcripts and
downregulating expression206,207 (Fig. 10). Loss of VEGF function could also have a
genetic basis independent of SOD1 mutations. Single-nucleotide polymorphisms in the
VEGF promoter region were found to correlate with an increased risk of ALS,26 although a
recent meta-analysis of available genotype data restricts this effect to males.208 Mutations in
ANG were also linked to a small subset of ALS cases.21–23 ALS-associated ANG mutations
occur at functionally important residues involved in catalysis and nuclear localization22
rather than hampering ANG expression, which is unchanged or even increased in ALS
patients and mouse models.209,210 The common functional consequence of ALS-associated
ANG mutations appears to be an inability to promote neural connectivity and survival.211
The relative contributions of these proteins’ neuroprotective and angiogenic properties to
CNS health are unknown, but there is evidence that deficiencies in both functions could
promote neurodegeneration. The neuroprotective effect of both VEGF and ANG in cell
culture90,204,211 gives strong evidence for neurotrophic action of these proteins independent
of vasculature. However, decreased cerebral blood flow in ALS patients212,213 and
disruptions in the blood–spinal cord barrier of several mouse models214 indicate that
vascular dysfunctions are indeed present in ALS. In mouse models of ALS, overexpression
of VEGF or its receptors, or administration of purified VEGF directly to the CNS, resulted
in neuroprotection and prolonged survival,215,216 leading to hope for VEGF administration
as a therapeutic strategy. Restoration of ANG activity may also hold therapeutic potential.
Further study is needed to explore this possibility and to resolve the molecular details of
ANG and VEGF action in the CNS.
One possible mechanism for VEGF-mediated neuroprotection is its antagonism of the axon
guidance protein Sema3A. Sema3A is a member of the semaphorin family of proteins,
which guide axons to their targets during development and also play a role in the complex
phenomena of neural network refinement and plasticity.217 Sema3A is a secreted
glycoprotein that acts as an axonal chemorepellent through binding of a neuropilin-1/plexin-
A coreceptor complex, which triggers downstream cytoskeletal reorganization and axon
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withdrawal.218 These receptor components are expressed throughout adulthood in spinal
cord motor axons, a sensitivity which allows them to avoid Sema3A-producing scar tissue
during post-injury regeneration.219–221 However, postnatal responsiveness to Sema3A may
be a liability in individuals with SOD1 mutations. Terminal Schwann cells of SOD1G93A
mice release abnormally high levels of Sema3A into the NMJ before symptom onset,219
which would be expected to induce axonal withdrawal from the synapse. Interestingly,
VEGF also binds neuropilin-1, leading some to propose that it prevents denervation in ALS
by competing with Sema3A for receptor binding.219
In addition to Sema3A, ALS patients show increased expression of other axonal
chemorepellents, including ephrinA1 in motor neurons196 and Nogo-A in muscle.222
Muscle-specific overexpression of the secreted factor Nogo-A induced axon retraction from
the NMJ in mice and higher Nogo-A expression in a subset of ALS patients correlated with
disease severity.223 Although the dysregulation of axonal guidance proteins is clearly
correlated with ALS pathology, there is no strong evidence for causation. In fact, Nogo-A
upregulation has been reported to occur in response to neuromuscular denervation,224 not
vice versa. However, overabundance of axonal chemorepellents at the NMJ following initial
retraction would certainly inhibit compensatory reinnervation and may transform a minor
insult into irreparable damage to the neuromuscular synapse (Fig. 9).
C. Axonal Structure and Transport Defects
The combination of polarity, high energetic demand, and extreme axon length (up to 1m)225
makes axonal integrity paramount to motor neuron viability. Accumulation of
neurofilaments, which maintain axonal diameter and structural integrity in motor neurons, is
a long-recognized hallmark of ALS pathology in humans and mouse models and is thought
to contribute to the selective vulnerability of long, large-caliber motor axons.2,48,226–228
Neurofilaments consist of light (NF-L), medium (NF-M), and heavy (NF-H) subunits, in
equal proportion, and their proper assembly is crucial to the maintenance and extension of
vulnerable large-caliber motor axons.229,230 Misassembly of neurofilaments due to over- or
under-expression, mutation, or deficient transport of individual subunits results in their
accumulation, further hindrance of axonal transport, and eventual motor neuron
death.231–236 Hyperphosphorylation of neurofilaments also contributes to defective transport
by causing their detachment from motor complexes and promoting aberrant self-
association.237–240 In ALS, this phenomenon is attributable to overactivation of p38 MAP
kinase and Cdk5, which phosphorylate NF-M and NF-H.241–243 Neurofilament
accumulation appears to be selectively deleterious to axons. Overexpression of NF-H causes
sequestration of neurofilaments within the cell body and perikarya and markedly delays
disease onset in mouse models of ALS.244 In addition to relieving the axonal burden of
neurofilament aggregates, thus facilitating transport, accumulated neurofilaments in the
perikarya are thought to counter glutamate excitotoxicity by chelating excess calcium and/or
binding the cytoplasmic domains of glutamate receptors.245,246
In addition to neurofilaments, axonal transport of many other cellular components is
indispensable for motor neuron health and homeostasis. Transport between the cell body and
neuromuscular synapse is mediated by the dynein/dynactin (retrograde) and kinesin
(anterograde) motor protein complexes, which carry adaptor-bound cargo along axonal
microtubules. Mutant SOD1 mice show presymptomatic defects in both anterograde and
retrograde transport,144,247,248 with a particular retardation in the trafficking of
mitochondria249,250 and cytoskeletal components such as neurofilament and tubulin
subunits.248 Mitochondria are normally enriched near the neuromuscular synapse to meet
the high energetic and calcium-buffering needs of the firing axon.251 Impaired anterograde
transport may thus explain the early onset distal axonopathy observed in ALS mouse
models. SALS patients show accumulation of mitochondria in proximal axons,252 which is
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further evidence for impaired anterograde transport as a fundamentally important
mechanism of all ALS pathology. As with several other pathological processes in SOD1-
related FALS, misfolding and aggregation directly impair axonal transport though aberrant
interactions. Mutant SOD1 acquires the ability to bind motor complexes that are
instrumental to both anterograde (kinesin-2253) and retrograde (dynein/dynactin254,255)
axonal transport (Fig. 10). Mutant SOD1 also interacts directly with the 3’-UTR of NF-L
mRNA,256 resulting in decreased expression that is observed in both FALS and SALS
patients.257–259
Because of its prevalence in human patients and early onset in ALS mouse models,
dysregulation of neurofilament transport and metabolism became an early candidate for a
common mechanism of ALS pathogenesis. While this hypothesis is attractive due to its
apparent specificity for motor axons, evidence for a primary role of axonal neurofilaments in
ALS is contradictory. While the aforementioned work by Couillard-Despres et al. indicates
that reducing axonal neurofilaments dramatically delays ALS pathology,244 a second study
showed no benefit from sequestration of neurofilaments in the cell body and perikarya.260 It
may be that neurofilament dysfunction modifies neurodegenerative severity in ALS but is
not sufficient to cause disease, a possibility that does not preclude defective axonal transport
as a primary mechanism of pathogenesis. The early retardation of both anterograde and
retrograde trafficking in motor axons undoubtedly initiates a spectrum of deleterious effects
such as energetic deficiencies at the distal synapse and impaired neuromuscular
communication. Further study is crucial to reveal the underlying mechanisms and
consequences of axonal transport malfunction in ALS and to identify targets for therapeutic
intervention.
D. Mitochondrial Dysfunction
Mitochondrial abnormalities such as swelling and vacuolization are pathological hallmarks
in spinal cords of ALS patients and most transgenic mouse models,49,107,121,261,262 leading
to much interest in the mitochondrion's involvement in disease. Perturbed energy
homeostasis and ATP deficits are observed in both SOD1G93A mice and skeletal muscle
biopsies from ALS patients.263–268 One mechanism by which the FALS mutant G93A
impairs cellular respiration is through a novel ability to bind cytosolic malate
dehydrogenase, which disrupts the malate–aspartate shuttle.269 Misfolded and aggregated
SOD1 mutants also accumulate on the cytoplasmic face of the outer mitochondrial
membrane and bind directly to the voltage-dependent anion channel (VDAC), depolarizing
the membrane and disrupting the normal functioning of the electron transport chain
(ETC)266,270–272 (Fig. 10). ETC dysfunction is a notable convergence in the pathologies of
sporadic and familial ALS, and ETC inhibition in SALS patients has been linked to
mutations in mitochondrial DNA.267,273,274 Mitochondrial genome instability has been
proposed (controversially) to play a central role in the natural aging process,275–279 which
would offer a possible basis for the late onset of disease in SALS. Interestingly, SOD1G93A
mice and a subset of sporadic ALS patients are hypermetabolic265,280 and administration of
a high-fat diet modestly improved survival in mice.265 The cause(s) and significance of
hypermetabolism are unknown, as are the mechanisms by which aberrant metabolic states
mediate toxicity in ALS. The surprising finding that metabolic dysfunction in skeletal
muscle can provoke motor neuron death145 suggests that mitochondrial defects may be
central to the retrograde neurodegeneration seen in mouse models of ALS.
Mitochondria are also key players in the buffering of intracellular calcium, which in
prolonged excess results in the activation of pro-oxidant and apoptotic factors such as nitric
oxide synthase (NOS), phospholipases, and endonucleases.281,282 ALS mice show a CNS-
specific decrease in mitochondrial calcium loading capacity that precedes motor deficits.283
Likewise, both ALS patients and mouse models have increased intracellular calcium
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concomitant with mitochondrial damage.283–285 It is not clear whether decreased
mitochondrial buffering capacity precedes cytosolic Ca2+ overload or vice versa, since these
processes reciprocally enhance each other167,286 (Fig. 10). Depletion of mitochondrial
calcium-buffering ability is particularly deleterious to neurons and skeletal muscle, whose
normal functioning involves frequent influxes of calcium to generate action potentials. This,
combined with the enrichment of mutant SOD1 in mitochondria of motor
neurons,266,271,272,287,288 muscle,137 and astrocytes,289 may account for the sensitivity of
these cells to mutant SOD1-mediated toxicity. Disturbance of mitochondrial function may
also directly cause cell death by activating the apoptotic cascade. Aberrant localization to
the intermembrane space and matrix288,290,291 disrupts the structural integrity of the
organelle, resulting in release of the apoptotic trigger cytochrome c.292 Misfolded SOD1
monomers and oligomers also provoke apoptosis by associating with the pro-survival factor
Bcl-2. The normally anti-apoptotic Bcl-2 exposes a toxic BH3 domain upon mutant SOD1
binding, resulting in cell death and interference of synaptic transmission at the NMJ.293–295
Given the presymptomatic, cell type-specific recruitment of mutant SOD1 to
mitochondria,271,287 dysfunctional changes in this organelle merit consideration as primary
contributors to ALS pathogenesis.
E. Deficient Protein Quality Control
The presence of proteinaceous aggregates in spinal cords of FALS and SALS patients
suggests that malfunction or overloading of protein quality control machinery is a common
feature of neurodegeneration. The ubiquitin–proteasome system (UPS), in which ubiquitin-
tagged proteins are targeted for proteasomal degradation, is one such mechanism of
misfolded protein clearance. Degradation of misfolded mutant SOD1 proceeds via the UPS
and impedes its functioning by sequestering proteasomal subunits and ubiquitin ligases such
as Dorfin,296–300 while proteasomal inhibition produces a reciprocal enhancement of SOD1
aggregation93,301,302 (Fig. 10). Ubiquitin- and ubiquitin ligase-positive intraneuronal
inclusion bodies are found in FALS mouse models47,303 and postmortem spinal cord of
SALS patients,124,300,304–306 indicating UPS activity and sequestration in both forms of the
disease. Studies of SOD1 mutant transgenic mice reveal proteasomal impairment in the
disease-vulnerable spinal cord and brainstem only after the onset of symptoms307,308; so
UPS dysfunction is unlikely to be an initiator of pathology in SOD1-related FALS.
Interestingly, as disease progresses, constitutively active proteasomal components are
replaced by inflammatory cytokine-responsive subunits to yield the inducible
“immunoproteasome”, which degrades proteins into antigenic peptide fragments to be
presented by the class 1 major histocompatibility complex.307,309,310 Inhibition of
immunoproteasome formation using a small-molecule anti-inflammatory agent shortens
survival in a rat model of ALS,311 but a more targeted genetic approach involving
knockdown of the LMP2 immunoproteasomal subunit yielded no effect on survival in
SOD1G93A mice.312 The role of the immunoproteasome in ALS pathology is yet to be
precisely determined, but its upregulation may be a response to glia-mediated inflammation
in the CNS.313,314
Protein quality control by ER-associated degradation (ERAD) is also impaired in ALS,
leading to stress signaling that can directly induce motor neuron death via activation of
apoptosis. During synthesis and maturation of nascent proteins in the ER, misfolded species
are cleared from the luminal space by the ERAD pathway (reviewed in Ref. 315).
Dysfunction or overloading of ERAD results in accumulation of unfolded proteins and
triggers the unfolded protein response (UPR).316,317 Mutant SOD1 interferes directly with
ERAD by binding to derlin-1, a transmembrane protein responsible for the translocation of
misfolded proteins from the ER lumen,318 as well as the ER-luminal chaperone BiP319 (Fig.
10). Sustained ER stress in SOD1 mutant mice leads to the activation of ASK1, an apoptotic
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protein kinase, and survival can be prolonged by ASK1 ablation.318 Derlin-1 interaction was
detected only after symptom onset,318 but multiple triggers of ER stress are clearly present
in ALS, as evidenced by presymptomatic UPR activation in SOD1 mutant mouse models320
and upregulation of UPR components in SALS patients.306,321,322 Furthermore, mutations in
the UPR protein VAPB have been linked to some ALS cases.20 Thus, ER stress may not be
ruled out as a primary contributor to ALS pathogenesis nor may its involvement be limited
to SOD1-related cases.
F. Aberrant RNA Processing
Malfunction and aggregation of two nucleic acid binding proteins was recently shown to be
a common causal factor for some cases of both familial and sporadic ALS. Since the
surprising observation that the 43-kDa trans-activating response region DNA-binding
protein (TDP-43) is present in a majority of ubiquitinated proteinaceous inclusions in ALS
and frontotemporal lobar degeneration (FTLD),323,324 over 35 dominant mutations in
TDP-43 have been linked to ALS.309,325–343 TDP-43 is notably excluded from inclusions of
patients with SOD1-related FALS,344 perhaps an indication of divergent pathological
mechanisms. However, it was recently shown that the small heat shock protein B8 (HspB8)
is involved in clearance of both SOD1 and TDP-43 aggregates,345 which is evidence that,
despite differences in etiology, TDP-43 and SOD1-related ALS may respond to similar
therapeutic approaches. Mutations in a second RNA/DNA-binding protein, fused in sarcoma
(FUS) (also known as translocation in liposarcoma (TLS)), have also been linked to ALS
and FTLD.346–360 This common genetic basis for ALS and FTLD blurs the distinction
between these disorders and may account for their co-occurance in some patients.8
The study of TDP-43- and FUS/TLS-related proteinopathies is a burgeoning field, as even
the normal functions of these proteins were not well understood prior to the revelation of
their roles in neurodegenerative diseases. Both proteins are widely expressed, predominantly
nuclear proteins in healthy cells361 and are involved in RNA processing events such as
splicing and transcriptional regulation (reviewed in Ref. 362). Cytoplasmic aggregation and
nuclear depletion are early, and perhaps independent, events in TDP-43-related ALS
pathology363–366 and are accompanied by proteolytic cleavage,324,367,368
hyperphosphorylation,367,369,370 and ubiquitination.323,324 The combination of aberrant
localization and posttranslational modification of TDP-43 in ALS raises the question of
whether TDP-43 pathogenicity is a loss or gain of function. Does toxicity stem from the loss
of normal TDP-43 nuclear function, or does cleaved, phosphorylated, or aggregated TDP-43
acquire cytotoxic properties? The TDP-43 C-terminal fragment is produced by caspase-3
cleavage371–374 and increases in abundance as symptoms progress, suggesting that
proteolysis of TDP-43 may be secondary to activation of apoptosis. Cytoplasmic inclusions
stain negative for several known binding partners of TDP-43,375 suggesting that aggregates
do not exert toxicity by sequestering these components. However, the possibility that altered
TDP-43 disrupts cellular homeostasis through novel aberrant interactions, as is the case with
misfolded SOD1, has not been ruled out. FUS/TLS, while also aggregating in the
cytoplasm,354,357,360 appears to retain a more normal pattern of localization in the ALS-
affected CNS, and neither phosphorylation nor cleavage is significantly correlated with
disease.354,357,360,370
Intense study is under way to clarify the cellular functions of TDP-43 and FUS/TLS and the
role of mutations in ALS and other neurodegenerative disorders. Interestingly, defective
RNA processing has been noted previously in ALS and shown to cause EAAT2
deficiency,376 a phenomenon that TDP-43 or FUS/TLS dysfunction may explain.
Elucidation of the roles of TDP-43 and FUS/TLS in RNA metabolism has the potential to
fill gaps in our understanding of numerous pathological deregulatory events in ALS.
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The molecular biology of ALS is extraordinarily complex, and identification of the crucial
initiating factors has remained elusive. However, a critical need exists for effective therapies
to prevent loss of motor function and extend life. This effort should be focused on
developing strategies for intervention at primary sites of dysfunction. In the case of SOD1-
related FALS, protein misfolding and aggregation and calcium dysregulation drive many of
the diverse pathological events in disease progression (Fig. 10) and should thus be
considered prime candidates for therapeutic targeting. Mutant SOD1 transgenic mice will
continue to be invaluable for mechanistic study of disease and development/evaluation of
drug candidates. However, these models should be evaluated critically for relevance based
on criteria such as copy numbers of wild-type and mutant SOD1 and presence of
posttranslational modifications that affect stability.
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El Escorial criteria for diagnosis of ALS. UMN = upper motor neuron; LMN = lower motor
neuron.
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Protein instability and aggregation propensity correlate with shorter survival times in SOD1-
related FALS. In all panels, data are weighted for linear regression analysis according to the
number of patients for which survival data was available. (A) The aggregation propensities
of FALS-causative SOD1 mutations are calculated using a rederivation of the Chiti–Dobson
equation,61 which was validated by comparison with available experimental data, and
normalized such that the least and most aggregation-prone proteins have values of 0 and 1,
respectively. (B) Protein instability is taken as 1 minus the change in free energy of
unfolding or change in melting temperature of the mutant protein compared to the wild type
(from published in vitro data). Instability values are normalized such that the most and least
stable proteins have values of 0 and 1, respectively. (C) Normalized sums of aggregation
propensity and protein instability values plotted against patient survival. From Wang et al.60
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Location of FALS-causative mutations on the SOD1 structure. (A) Map of SOD1 secondary
structure showing locations of FALS missense mutations, residues that coordinate Cu2+
(His-46, His-48, His-120, His-63) and Zn2+ (His-63, His-71, His-80, and Asp-83) ions, and
the intramolecular disulfide bridge. Arrows indicate β-strands. Epidemiological data were
taken from Refs. 45,60,70–73; mutations with survival data for at least five patients are
bolded, and the residue position is shaded to indicate the corresponding average survival
time. For positions with more than one n≥5 mutation, the upper color corresponds to the first
mutation listed. (B) Crystal structure (PDB code 1spd) of fully mature (metal-bound,
disulfide-intact) homodimeric SOD1 with positions of aggressive (survival time <5 years)
mutations indicated by black spheres.
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General mechanism of SOD1 aggregation.
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Coexpression of wild-type SOD1 exacerbates the phenotype of FALS mutant transgenic
mice. Survival and symptom onset are plotted versus age for mice expressing G93A, A4V,
and L126Z (truncation) mutants of SOD1 with and without coexpression of the human wild-
type enzyme (hwtSOD1). From Deng et al.92 Copyright 2006 National Academy of
Sciences, USA.
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Motor neuron death in ALS is not cell autonomous. Table below the figure summarizes
findings of studies using transgenic mouse models with tissue-specific mutant SOD1
expression or Cre–Lox/siRNA knockdown of ubiquitously expressed mutant SOD1.
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Timeline of molecular and cellular pathologies in transgenic mice ubiquitously expressing
SOD1G93A. The “symptomatic” stage denotes the period following initial onset of muscle
weakness and wasting (80–100 days). Dates of pathology appearance taken from.44,91,114
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Glutamate excitotoxicity causes influx of Ca2+ to motor neurons and activates apoptosis.
ALS patients and mouse models have decreased levels of the astrocytic glutamate
transporter EAAT2/GLT1, which clears glutamate from the synapse after firing.
Dysfunction in the presynaptic motor axon disrupts activation of the EAAT2/GLT1
transcriptional activator κB motif binding phosphoprotein (KBBP). Deficient EAAT2/
GLT1, combined with inactivation of the transporter by oxidative damage and caspase-3-
mediated proteolysis, results in persistent glutamate stimulation of the Ca2+-permeable
AMPA receptor, which is especially abundant in motor neurons. The resultant calcium
influx activates several pro-oxidant and pro-apoptotic factors and prolonged Ca2+ excess
results in motor neuron death.
Redler and Dokholyan Page 43














Aberrant expression of neurotrophic and axonal guidance factors at the neuromuscular
junction of SOD1G93A mice. Expression of the neuroprotective vascular endothelial growth
factor (VEGF) is decreased because of the binding of mutant SOD1 to the 3′-untranslated
region of VEGF mRNA, while expression of the axonal chemorepellents Sema3A and
Nogo-A is upregulated in terminal Schwann cells and muscle, respectively. Loss of trophic
support and increased repulsive cues may induce withdrawal of the motor axon from the
neuromuscular synapse.
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Diverse pathological processes in SOD1-related FALS are highly interrelated and many
stem directly from SOD1 misfolding/aggregation and cytosolic calcium overload.
Abbreviations: mutSOD1, mutant SOD1; UTR, untranslated region; VDAC, voltage-
dependent anion channel; ETC, electron transport chain; UPR, unfolded protein response;
ROS/RNS, reactive oxygen/nitrogen species.
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TABLE I
Genetic Loci Associated with ALS
Locus Chromosome Gene Characteristics
Classical ALS ALS1 12q22.1 Superoxide dismutase 1 (SOD1) AD, adult onset
ALS2 2q33 Alsin AR, juvenile onset
ALS3 18q21 Unknown AD, adult onset
ALS4 9q34 Senataxin (SETX) AD, juvenile onset
ALS5 15q15.1–21.1 Unknown AR, juvenile onset
ALS6 16q12.1–12.2 Fused in sarcoma (FUS) AD, adult onset
ALS7 20p13 Unknown AD, adult onset
ALS8 20q13.33 Vesicle-associated membrane protein-associated protein B (VAPB) AD, adult onset
ALS9 14q11 Angiogenin (ANG) AD, adult onset
ALS10 1p36 Tar DNA-binding protein (TARDBP) AD, adult onset
Atypical ALS
ALSX X Unknown XD, adult onset
ALS/FTLD 9q21–22
9p13.3–21.3
Unknown XD, adult onset
ALS–PDC 17q21.1 Membrane-associated protein tau (MAPT) AD, adult onset
AD, autosomal dominant; AR, autosomal recessive; XD, X-linked dominant; FTLD, frontotemporal lobar dementia; PDC, Parkinsonism-dementia
complex.
Updated references for each locus at the ALS Online Genetics Database (http://alsod.iop.kcl.ac.uk).
Gray-shaded areas are alternated with unshaded rows to improve readability of the table
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